Printer Friendly

Cantargia reports treatment of first patient with antibody CAN04 in the phase IIa part of CANFOUR trial.

NORDIC BUSINESS REPORT-January 28, 2019-Cantargia reports treatment of first patient with antibody CAN04 in the phase IIa part of CANFOUR trial


Cantargia AB (STO:CANTA), a biotechnology company that develops antibody-based treatments for life-threatening diseases, announced on Friday the receipt by the first patient in the phase IIa part of the CANFOUR clinical trial of CAN04 (nidanilimab) treatment in accordance with the clinical protocol.

According to the company, the first infusion of CAN04 in the phase IIa part of the clinical trial has now been administrated to a patient in accordance with the clinical protocol.

Reportedly, the CANFOUR trial investigates the antibody CAN04 for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. CAN04 is targeted against interleukin 1 receptor accessory protein (IL1RAP) and is studied both as single agent therapy, as well as in combination with standard first line chemotherapy in NSCLC and pancreatic cancer, respectively.

Cantargia is developing the antibody CAN04 for treatment of cancer. CAN04 is investigated in the CANFOUR phase I/IIa clinical trial. CAN04 is directed against IL1RAP which is found on tumour cells from a large number of cancer forms and the CANFOUR trial is primarily focused on treatment of NSCLC and pancreatic cancer. IL1RAP is also found on inflammatory immune cells contributing to the cancer progression.

Cantargia added that positive phase I interim data in heavily pre-treated patients was presented in October 2018 at ESMO, showing good safety, effects on relevant biomarkers and stable disease in 38% of patients. The recommended phase IIa dose of 10 mg/kg has been established during the phase I part of the trial.

This trial is performed in western Europe and is planned to expand from the five current clinical centres to approximately 20 sites in seven countries. Screening of patients is ongoing with the goal to recruit approximately 20 patients for monotherapy treatment and 30 patients in each combination cohort.

((Comments on this story may be sent to

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Nordic Business Report
Geographic Code:4EUSW
Date:Jan 28, 2019
Previous Article:Ahlstrom-MunksjA[pilcrow sign] reports on board proposals of shareholders' nomination board to the AGM 2019.
Next Article:Bygmaxx Group reports profit of SEK137.6m in 2018.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters